Ueda, K.; Ogasawara, N.; Ito, N.; Ohnishi, S.; Suekane, H.; Kurose, H.; Hiroshige, T.; Chikui, K.; Uemura, K.; Nishihara, K.;
et al. Prognostic Value of Absolute Lymphocyte Count in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab Plus Ipilimumab. J. Clin. Med. 2023, 12, 2417.
https://doi.org/10.3390/jcm12062417
AMA Style
Ueda K, Ogasawara N, Ito N, Ohnishi S, Suekane H, Kurose H, Hiroshige T, Chikui K, Uemura K, Nishihara K,
et al. Prognostic Value of Absolute Lymphocyte Count in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab Plus Ipilimumab. Journal of Clinical Medicine. 2023; 12(6):2417.
https://doi.org/10.3390/jcm12062417
Chicago/Turabian Style
Ueda, Kosuke, Naoyuki Ogasawara, Naoki Ito, Satoshi Ohnishi, Hiroki Suekane, Hirofumi Kurose, Tasuku Hiroshige, Katsuaki Chikui, Keiichiro Uemura, Kiyoaki Nishihara,
and et al. 2023. "Prognostic Value of Absolute Lymphocyte Count in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab Plus Ipilimumab" Journal of Clinical Medicine 12, no. 6: 2417.
https://doi.org/10.3390/jcm12062417
APA Style
Ueda, K., Ogasawara, N., Ito, N., Ohnishi, S., Suekane, H., Kurose, H., Hiroshige, T., Chikui, K., Uemura, K., Nishihara, K., Nakiri, M., Suekane, S., & Igawa, T.
(2023). Prognostic Value of Absolute Lymphocyte Count in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab Plus Ipilimumab. Journal of Clinical Medicine, 12(6), 2417.
https://doi.org/10.3390/jcm12062417
